[{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"e9758ac4-aa20-4e05-8191-60a5341872f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04205630","created_at":"2021-01-18T20:29:12.666Z","updated_at":"2024-07-02T16:35:00.063Z","phase":"Phase 2","brief_title":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma","source_id_and_acronym":"NCT04205630","lead_sponsor":"Byondis B.V.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Jivadco (trastuzumab duocarmazine)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 04/25/2023","study_completion_date":" 04/25/2023","last_update_posted":"2024-05-30"},{"id":"7eb7e662-eaed-4643-b83d-3d968c7c14d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04983238","created_at":"2021-07-30T17:54:56.973Z","updated_at":"2024-07-02T16:35:24.411Z","phase":"Phase 1/2","brief_title":"Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985","source_id_and_acronym":"NCT04983238","lead_sponsor":"Byondis B.V.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jivadco (trastuzumab duocarmazine)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 01/10/2022","start_date":" 01/10/2022","primary_txt":" Primary completion: 04/19/2023","primary_completion_date":" 04/19/2023","study_txt":" Completion: 06/26/2023","study_completion_date":" 06/26/2023","last_update_posted":"2024-01-05"},{"id":"b772384b-ce1a-4b84-a08f-e6646f70a58b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04235101","created_at":"2021-01-18T20:35:55.656Z","updated_at":"2024-07-02T16:35:24.393Z","phase":"Phase 1","brief_title":"Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors","source_id_and_acronym":"NCT04235101","lead_sponsor":"Byondis B.V.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Zejula (niraparib) • Jivadco (trastuzumab duocarmazine)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 06/22/2020","start_date":" 06/22/2020","primary_txt":" Primary completion: 04/24/2023","primary_completion_date":" 04/24/2023","study_txt":" Completion: 04/24/2023","study_completion_date":" 04/24/2023","last_update_posted":"2024-01-05"},{"id":"9691f487-0085-4e15-862b-15967cf70ec4","acronym":"TULIP","url":"https://clinicaltrials.gov/study/NCT03262935","created_at":"2021-01-18T16:07:05.359Z","updated_at":"2024-07-02T16:35:32.477Z","phase":"Phase 3","brief_title":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT03262935 - TULIP","lead_sponsor":"Byondis B.V.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jivadco (trastuzumab duocarmazine)"],"overall_status":"Completed","enrollment":" Enrollment 437","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2023-10-19"},{"id":"e0fe501a-254b-4ce1-8e4d-60381765a618","acronym":"","url":"https://clinicaltrials.gov/study/NCT02277717","created_at":"2021-01-17T17:55:42.454Z","updated_at":"2024-07-02T16:35:40.319Z","phase":"Phase 1","brief_title":"First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients","source_id_and_acronym":"NCT02277717","lead_sponsor":"Byondis B.V.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Jivadco (trastuzumab duocarmazine)"],"overall_status":"Completed","enrollment":" Enrollment 185","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2023-08-11"}]